Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to “Sell” at StockNews.com

StockNews.com downgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a sell rating in a report published on Friday.

AGIO has been the subject of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Scotiabank upped their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Finally, Royal Bank of Canada lifted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO opened at $33.22 on Friday. The company has a market capitalization of $1.89 billion, a P/E ratio of 2.92 and a beta of 0.88. The stock’s 50 day moving average price is $35.19 and its 200 day moving average price is $43.41. Agios Pharmaceuticals has a 52 week low of $24.88 and a 52 week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.93% and a net margin of 2,051.38%. As a group, sell-side analysts forecast that Agios Pharmaceuticals will post -0.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of AGIO. Erste Asset Management GmbH acquired a new stake in shares of Agios Pharmaceuticals in the third quarter worth $97,199,000. Vestal Point Capital LP acquired a new stake in shares of Agios Pharmaceuticals in the third quarter worth $33,767,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth $9,957,000. State Street Corp grew its stake in shares of Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after acquiring an additional 216,484 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. grew its stake in shares of Agios Pharmaceuticals by 19.7% in the third quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock worth $46,392,000 after acquiring an additional 172,180 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.